Retrospective analyses have shown that PD-L1 positivity in tumor cells, as detected by immunohistochemistry, may predict an improved response to anti-PD-1/PD-L1 therapy in melanoma (29), non-small-cell lung carcinoma (30), breast cancer (31), esophageal adenocarcinoma (32), glioblastoma (33), renal cell carcinoma (34), pancreatic carcinoma (35) and urothelial carcinoma (36). The gene discussed is CD274; the disease is hereditary clear cell renal cell carcinoma.